# Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints

> **NCT02349607** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-05089771 300mg
- **DRUG:** PF-05089771 300 mg + pregabalin 300 mg
- **DRUG:** Placebo
- **DRUG:** pregabalin 300 mg
- **DRUG:** ibuprofen 600 mg

## Key facts

- **NCT ID:** NCT02349607
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349607, "Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02349607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*